αPD‐L1 therapy is one of the most hopeful immunotherapies for lung cancer, and tumor PD‐L1 expression is an essential determinant.[4b] However, the immune response is dynamic, and there is still a large part of lung cancer patients who are poor responders, especially patients carrying low‐expressed PD‐L1. This evidence concerns the gene CD274 and lung cancer.